Atlas Oncology Partners has raised $28 million in a Series A financing to expand its value-based oncology enablement platform, which embeds interdisciplinary care teams inside community oncology practices and takes on full medical cost risk in arrangements with payors.
The round was led by Flare Capital Partners, with significant participation from Rubicon Founders, the healthcare investment firm that founded Atlas. The company said the new capital will support geographic expansion through additional oncology practice partnerships and continued investment in clinical and operational infrastructure.
Atlas is positioning its model as a response to cancer care that is often fragmented and difficult for patients to navigate, particularly as they manage complex clinical needs alongside social and logistical challenges. The company places teams that can include providers, nurses, patient navigators, and social workers directly within oncology practices to coordinate care during treatment and beyond.
The platform’s approach combines patient navigation, psychosocial and supportive care, proactive care coordination, and broader in-person and virtual clinical access. Atlas said it aligns incentives with medical oncology practice partners by assuming full medical cost risk and investing in partner operations to support high-quality delivery, with the goal of reducing avoidable costs and easing the financial burden on patients.
KEY QUOTES
“From the moment of diagnosis, patients can feel overwhelmed by the complexity of cancer care. Atlas was built to simplify that experience by embedding holistic, coordinated support into oncology practices. This investment enables us to scale our model and reach more patients while staying true to our mission of improving quality of life and outcomes.”
Kate Barnard Roberts, President And Co Founder, Atlas Oncology Partners
“We incubated and invested in Atlas Oncology Partners to fundamentally rethink how cancer care is delivered. By embedding interdisciplinary teams directly into oncology practices and assuming full medical cost risk, Atlas is building a scalable model that improves outcomes, experience, and affordability.”
Matt Kim, Partner, Rubicon Founders
“Atlas Oncology Partners is addressing one of the most complex and costly areas of healthcare with a model that is deeply aligned with patients, oncologists, and payers at the forefront of value-based care. We are excited to lead their Series A and support Atlas as it scales the next-generation value-based oncology model — one that empowers community oncology groups to deliver coordinated, holistic care at scale and drives impactful clinical outcomes for patients and families impacted by cancer.”
Ian Chiang, Partner, Flare Capital Partners
